Melatonin: A Molecule for Reducing Breast Cancer Risk

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2018 Feb 9

PMID 29415446

Citations 24

Authors

Alicia Gonzalez-Gonzalez

Maria Dolores Mediavilla

Emilio J Sanchez-Barcelo

Affiliations

Soon will be listed here.

Abstract

The objective of this article is to review the basis supporting the usefulness of melatonin as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high risk for this disease. Melatonin, as a result of its antiestrogenic and antioxidant properties, as well as its ability to improve the efficacy and reduce the side effects of conventional antiestrogens, could safely be associated with the antiestrogenic drugs presently in use. In individuals at risk of BC due to night shift work, the light-induced inhibition of melatonin secretion, with the consequent loss of its antiestrogenic effects, would be countered by administering this neurohormone. BC risk from exposure to metalloestrogens, such as cadmium, could be treated with melatonin supplements to individuals at risk of BC due to exposure to this xenoestrogen. The BC risk related to obesity may be reduced by melatonin which decrease body fat mass, inhibits the enhanced aromatase expression in obese women, increases adiponectin secretion, counteracts the oncogenic effects of elevated concentrations of leptin; and decreases blood glucose levels and insulin resistance. Despite compelling experimental evidence of melatonin's oncostatic actions being susceptible to lowering BC risk, there is still a paucity of clinical trials focused on this subject.

Citing Articles

The clinical impact of chronopharmacology on current medicine.

Kaskal M, Sevim M, Ulker G, Keles C, Bebitoglu B Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39792169 DOI: 10.1007/s00210-025-03788-7.

Significance of Melatonin in the Regulation of Circadian Rhythms and Disease Management.

Megha K, Arathi A, Shikha S, Alka R, Ramya P, Mohanan P Mol Neurobiol. 2024; 61(8):5541-5571.

PMID: 38206471 DOI: 10.1007/s12035-024-03915-0.

Review Article a Multidisciplinary Evaluation for Advanced Supportive Care of Breast Cancer Patients.

Petrone A, Carlesimo M, Fortuna M, Peccatori F, Codacci-Pisanelli G, Barbara R Breast Care (Basel). 2023; 18(2):141-149.

PMID: 37261129 PMC: 10228256. DOI: 10.1159/000528280.

Preclinical Effects of Melatonin on the Development of Ehrlich's Tumor: A Biochemical, Cognitive, and Molecular Approach.

Lopes I, Bagatela B, Lopes A, Silveira E, Petri G, Santos J Recent Pat Anticancer Drug Discov. 2023; 20(1):113-120.

PMID: 36825727 DOI: 10.2174/1574892818666230223160858.

Melatonin and 5-fluorouracil combination chemotherapy: opportunities and efficacy in cancer therapy.

Mafi A, Rezaee M, Hedayati N, Hogan S, Reiter R, Aarabi M Cell Commun Signal. 2023; 21(1):33.

PMID: 36759799 PMC: 9912526. DOI: 10.1186/s12964-023-01047-x.

References

Hunter C, Figueiro M . Measuring Light at Night and Melatonin Levels in Shift Workers: A Review of the Literature. Biol Res Nurs. 2017; 19(4):365-374. PMC: 5862149. DOI: 10.1177/1099800417714069. View

Morimoto L, White E, Chen Z, Chlebowski R, Hays J, Kuller L . Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002; 13(8):741-51. DOI: 10.1023/a:1020239211145. View

Martinez-Campa C, Gonzalez A, Mediavilla M, Alonso-Gonzalez C, Alvarez-Garcia V, Sanchez-Barcelo E . Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer. 2009; 101(9):1613-9. PMC: 2778514. DOI: 10.1038/sj.bjc.6605336. View

Feskanich D, Hankinson S, Schernhammer E . Nightshift work and fracture risk: the Nurses' Health Study. Osteoporos Int. 2008; 20(4):537-42. PMC: 2651998. DOI: 10.1007/s00198-008-0729-5. View

Martinez-Campa C, Alonso-Gonzalez C, Mediavilla M, Cos S, Gonzalez A, Ramos S . Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J Pineal Res. 2006; 40(4):291-6. DOI: 10.1111/j.1600-079X.2006.00315.x. View

Anisimov V, Egormin P, Piskunova T, Popovich I, Tyndyk M, Yurova M . Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 2009; 9(1):188-97. DOI: 10.4161/cc.9.1.10407. View

Alonso-Gonzalez C, Gonzalez A, Mazarrasa O, Guezmes A, Sanchez-Mateos S, Martinez-Campa C . Melatonin prevents the estrogenic effects of sub-chronic administration of cadmium on mice mammary glands and uterus. J Pineal Res. 2007; 42(4):403-10. DOI: 10.1111/j.1600-079X.2007.00434.x. View

Mesri Alamdari N, Mahdavi R, Roshanravan N, Lotfi Yaghin N, Ostadrahimi A, Faramarzi E . A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women. Horm Metab Res. 2014; 47(7):504-8. DOI: 10.1055/s-0034-1384587. View

Jin T, Lu J, Nordberg M . Toxicokinetics and biochemistry of cadmium with special emphasis on the role of metallothionein. Neurotoxicology. 1998; 19(4-5):529-35. View

10.

Macis D, Guerrieri-Gonzaga A, Gandini S . Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. Int J Epidemiol. 2014; 43(4):1226-36. PMC: 4258781. DOI: 10.1093/ije/dyu088. View

11.

Cantor K, Stewart P, Brinton L, Dosemeci M . Occupational exposures and female breast cancer mortality in the United States. J Occup Environ Med. 1995; 37(3):336-48. DOI: 10.1097/00043764-199503000-00011. View

12.

Xiang S, Dauchy R, Hauch A, Mao L, Yuan L, Wren M . Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. J Pineal Res. 2015; 59(1):60-9. PMC: 4490975. DOI: 10.1111/jpi.12239. View

13.

DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B . Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3(11):1451-61. DOI: 10.1158/1940-6207.CAPR-10-0157. View

14.

Kotlarczyk M, Lassila H, ONeil C, DAmico F, Enderby L, Witt-Enderby P . Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res. 2012; 52(4):414-26. DOI: 10.1111/j.1600-079X.2011.00956.x. View

15.

Yuan L, Collins A, Dai J, Dubocovich M, Hill S . MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol. 2002; 192(1-2):147-56. DOI: 10.1016/s0303-7207(02)00029-1. View

16.

Dieudonne M, Serazin-Leroy V, Leneveu M, Pecquery R, Giudicelli Y . Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2002; 293(1):622-8. DOI: 10.1016/S0006-291X(02)00205-X. View

17.

Sadeghniiat-Haghighi K, Bahrami H, Aminian O, Meysami A, Khajeh-Mehrizi A . Melatonin therapy in shift workers with difficulty falling asleep: A randomized, double-blind, placebo-controlled crossover field study. Work. 2016; 55(1):225-230. DOI: 10.3233/WOR-162376. View

18.

Bjarnason G, Jordan R . Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. Prog Cell Cycle Res. 2000; 4:193-206. DOI: 10.1007/978-1-4615-4253-7_17. View

19.

Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295(23):2727-41. DOI: 10.1001/jama.295.23.joc60074. View

20.

Strumylaite L, Bogusevicius A, Abdrachmanovas O, Baranauskiene D, Kregzdyte R, Pranys D . Cadmium concentration in biological media of breast cancer patients. Breast Cancer Res Treat. 2010; 125(2):511-7. DOI: 10.1007/s10549-010-1007-8. View